Clinical Trial

A Clinical Trial to Evaluate Effect of IBB0979 in Patients With Advanced Malignant Tumors

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated January 17, 2025 (before its estimated November 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
This is a Phase 1/2, open-label, dose escalation and dose expansion study designed to characterize the safety, tolerability, PK, immunogenicity, and preliminary antitumor activity of IBB0979 in previously treated patients with locally advanced or metastatic solid tumors.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2023-08-07.
Trial Details
NCT Number NCT05991583
Lead Sponsor SUNHO（China）BioPharmaceutical CO., Ltd.
Conditions Advanced Malignant Tumors
Enrollment 25 participants
Start Date 2023-07-03
Primary Completion 2025-11-30 (estimated)
Study Completion 2025-12-30 (estimated)
Updated on ClinicalTrials.gov 2025-01-17